LBA36 - Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab…
jwood@krftwrk.caNovember 14, 2018
LBA12_PR - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with…
jwood@krftwrk.caNovember 14, 2018
LBA50 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III…
jwood@krftwrk.caNovember 14, 2018
LBA67 - Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group…
jwood@krftwrk.caNovember 14, 2018
Chronic Lymphocytic Leukemia: Ibrutinib Monotherapy EHA 2017. S769. Long-term Efficacy and Safety with Ibrutinib in…
jwood@krftwrk.caAugust 1, 2017
On January 13th, 2017 CARE™ faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology…
jwood@krftwrk.caJanuary 23, 2017
SABCS 2016. P5-16-17. Population based long-term outcomes of pathologic complete response after neoadjuvant chemotherapy in…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. P4-22-13. Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. S1-03. First results from the multicenter phase III DATA study comparing 3 versus…
jwood@krftwrk.caDecember 21, 2016
